Established in 2018, Xellera Therapeutics runs Hong Kong’s first commercial cGMP facility dedicated to cell and gene therapies. We provide end-to-end CDMO services—including process development, manufacturing, testing, and cryostorage—aligned with US FDA, EMA, and PIC/S standards to drive ATMP advancement in Asia. https://www.xelleratherapeutics.com/